Hemanext Completes Series B-3 Funding Round
Hemanext Inc., a prominent innovator in blood processing, storage, and transfusion technologies, has successfully closed its Series B-3 equity financing round. This round has generated $18.9 million at a post-money valuation of $172 million. Hemanext has welcomed new investors while also securing contributions from those who participated in the previous Series B-2 capital round.
Raising Funds to Drive Innovation
The funds raised through this financing are targeted towards enhancing Hemanext's commercial and clinical objectives in the near future, paving the way for a planned institutional Series C financing. The company aims to strengthen its market position and accelerate the development of its groundbreaking products.
Introducing the HEMANEXT ONE System
The HEMANEXT ONE RBC Processing and Storage system is a revolutionary technology that limits oxygen exposure, thereby preventing oxidative damage and ensuring a higher quality blood product. This innovation holds promise for patients across a range of chronic conditions requiring transfusions, including those with thalassemia and sickle cell disease, as well as during critical medical procedures.
Regulatory Approvals and Market Readiness
The HEMANEXT ONE system has been granted marketing authorization from the U.S. Food and Drug Administration using the De Novo pathway, and it also holds patents and CE marking for distribution within the European Economic Area. This broad array of approvals positions Hemanext favorably in the competitive blood processing market.
Pioneering Trends in Transfusion Therapy
Hemanext is dedicated to improving the efficiency of transfusion therapy by offering products that integrate seamlessly into existing medical workflows. The transitions require minimal training for clinicians and no additional equipment for implementation, thereby encouraging faster adoption.
Current Clinical Applications and Trials
Several hospitals are already utilizing hypoxic RBCs produced through the HEMANEXT ONE system to treat patients, while notable institutions are actively validating this new technique. Hemanext has reached significant milestones, including producing hypoxic RBCs at Vitalant, one of the largest nonprofit blood centers, and validating the system at prestigious medical institutions.
Strategic Goals for Financial Proceeds
Looking ahead, the capital from the B3 round will enable Hemanext to execute vital commercial strategies through early 2026. These efforts will involve expanding early-access use in hospitals and blood centers, generating real-world data on transfusions, and leveraging established payment pathways to facilitate customer adoption.
Transforming Transfusion Care
Andrew Dunham, CEO of Hemanext, expressed gratitude to both existing and new investors, emphasizing the trust and confidence in the company’s vision. He remarked that the funds would help generate the necessary commercial evidence to significantly boost revenue in 2026.
A Vision for the Future
Steve Eckert, Chairman of the Board, highlighted the strong belief in Hemanext’s potential to enhance patient care services through innovative methods that protect the viability and functionality of red blood cells. The dual commitment to patient health and customer satisfaction creates significant value for stakeholders in the healthcare ecosystem.
About Hemanext
Hemanext is a privately held medical technology firm dedicated to enhancing the quality and safety of transfusion therapy. Focused on the development of hypoxically stored RBCs, the company aims to make a meaningful impact on the global quality of blood storage.
Frequently Asked Questions
What is the significance of the Series B-3 funding for Hemanext?
The Series B-3 funding is crucial for Hemanext to advance its innovative blood processing technologies and to meet its strategic clinical and commercial objectives.
How does the HEMANEXT ONE system improve blood transfusions?
The HEMANEXT ONE system enhances blood quality by limiting oxygen exposure, which reduces oxidative damage to red blood cells.
Where is Hemanext currently deploying its technology?
Hemanext is currently producing hypoxic red blood cells at Vitalant and has initiated trials at various prestigious medical institutions in the U.S. and Europe.
What are the plans for the funds raised in the Series B-3 round?
The funds will support the expansion of product deployments, real-world data generation, and customer adoption programs through Q1 2026.
How does Hemanext ensure compliance with health regulations?
The HEMANEXT ONE system has received marketing authorization from the FDA and CE marking, ensuring regulatory compliance for safe medical use.
